Video
Dr. Miron on first-line treatment selection in bladder cancer
Author(s):
Video Player is loading.
Benjamin Miron, MD, shares his expertise on treatment selection in the first-line setting for patients with urothelial carcinoma.
Miron, a second-year hematology/oncology fellow at Fox Chase Cancer Center, presented a real-world study at the 2021 ASCO Annual Meeting that explored the influence of first-line chemotherapy choice on overall survival outcomes in patients with advanced urothelial carcinoma who received immunotherapy in the second-line setting.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUC
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Related Content
